 Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F the Company, an international biopharmaceutical company, today confirmed the financing requirements to maintain ongoing business operations. During a hearing before the Higher Regional Court of Cologne to review the Companys request to release an authorized capital approved by the 2017 Annual General Meeting, the Company was requested to elaborate on the financing needs stated in the 2019 financial statements. 